No one would argue that MSB hasn’t spent a lot of capital, that isn’t the point and doesn’t really answer my question. I am interested in whether they are at a stalemate while trying to resolve the potency issues or whether trials are allowed to move forward in tandem. Obviously the timeline is a concern given the cash balance.
disclosure - I held MSB a few years ago (before COVID) and sold for a healthy profit, holding through phase 3 trial results didn’t suit my risk appetite.
replying to @Sector above
No one would argue that MSB hasn’t spent a lot of capital, that...
-
- There are more pages in this discussion • 77 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.055(5.24%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.13 | $1.04 | $6.781M | 6.207M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 43856 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 66000 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |